These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 34466336)

  • 1. An update on China's national policies regarding rare diseases.
    Ying Z; Gong L; Li C
    Intractable Rare Dis Res; 2021 Aug; 10(3):148-153. PubMed ID: 34466336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Marketing of drugs for rare diseases is speeding up in China: Looking at the example of drugs for mucopolysaccharidosis.
    Kang Q; Hu J; Yang N; He J; Yang Y; Tang M; Jin C
    Intractable Rare Dis Res; 2019 Aug; 8(3):165-171. PubMed ID: 31523593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating the national system for rare diseases in China from the point of drug access: progress and challenges.
    Qiao L; Liu X; Shang J; Zuo W; Xu T; Qu J; Jiang J; Zhang B; Zhang S
    Orphanet J Rare Dis; 2022 Sep; 17(1):352. PubMed ID: 36088349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overview on social security system of rare diseases in China.
    He J; Song P; Kang Q; Zhang X; Hu J; Yang Y; Tang M; Chen D; Hu S; Jin C
    Biosci Trends; 2019 Sep; 13(4):314-323. PubMed ID: 31434816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical Insurance Information Systems in China: Mixed Methods Study.
    Li Y; Lu C; Liu Y
    JMIR Med Inform; 2020 Sep; 8(9):e18780. PubMed ID: 32673209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health service security of patients with 8 certain rare diseases: evidence from China's national system for health service utilization of patients with healthcare insurance.
    Min R; Zhang X; Fang P; Wang B; Wang H
    Orphanet J Rare Dis; 2019 Aug; 14(1):204. PubMed ID: 31429789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The availability and affordability of orphan drugs for rare diseases in China.
    Gong S; Wang Y; Pan X; Zhang L; Huang R; Chen X; Hu J; Xu Y; Jin S
    Orphanet J Rare Dis; 2016 Feb; 11():20. PubMed ID: 26920579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Network established to collaborate on diagnosis and treatment of rare diseases in China: A strategic alliance backed by tiered healthcare is the key to the future.
    Ren Q; Wang J
    Intractable Rare Dis Res; 2019 Feb; 8(1):78-79. PubMed ID: 30881864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. China has officially released its first national list of rare diseases.
    He J; Kang Q; Hu J; Song P; Jin C
    Intractable Rare Dis Res; 2018 May; 7(2):145-147. PubMed ID: 29862160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accessibility of drugs for rare diseases in China: Policies and current situation.
    Yang Y; Kang Q; Hu J; Kong F; Tang M; He J; Jin C
    Intractable Rare Dis Res; 2019 May; 8(2):80-88. PubMed ID: 31218157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toward the development of a vibrant, super-aged society: The future of medicine and society in Japan.
    Iijima K; Arai H; Akishita M; Endo T; Ogasawara K; Kashihara N; Hayashi YK; Yumura W; Yokode M; Ouchi Y
    Geriatr Gerontol Int; 2021 Aug; 21(8):601-613. PubMed ID: 34212470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expanding public health in China: an empirical analysis of healthcare inputs and outputs.
    Deng F; Lv JH; Wang HL; Gao JM; Zhou ZL
    Public Health; 2017 Jan; 142():73-84. PubMed ID: 28057203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and prevalence of 121 rare diseases in China: Current status and challenges.
    He J; Tang M; Zhang X; Chen D; Kang Q; Yang Y; Hu J; Jin C; Song P
    Intractable Rare Dis Res; 2019 May; 8(2):89-97. PubMed ID: 31218158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
    Rodriguez-Monguio R; Spargo T; Seoane-Vazquez E
    Orphanet J Rare Dis; 2017 Jan; 12(1):1. PubMed ID: 28057032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and prevalence of 121 rare diseases in China: Current status and challenges: 2022 revision.
    Lu Y; Gao Q; Ren X; Li J; Yang D; Zhang Z; Han J
    Intractable Rare Dis Res; 2022 Aug; 11(3):96-104. PubMed ID: 36200031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An early examination of access to select orphan drugs treating rare diseases in health insurance exchange plans.
    Robinson SW; Brantley K; Liow C; Teagarden JR
    J Manag Care Spec Pharm; 2014 Oct; 20(10):997-1004. PubMed ID: 25278322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries.
    Gammie T; Lu CY; Babar ZU
    PLoS One; 2015; 10(10):e0140002. PubMed ID: 26451948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Focusing on basic data and a model of healthcare security for rare diseases: The Multidisciplinary Expert Seminar on Healthcare Security for Rare Diseases in China was held in Beijing.
    Kang Q; Jin C; Li D
    Intractable Rare Dis Res; 2019 Aug; 8(3):224-225. PubMed ID: 31523605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Innovation in Informatics to Improve Clinical Care and Drug Accessibility for Rare Diseases in China.
    Liu P; Gong M; Li J; Baynam G; Zhu W; Zhu Y; Chen L; Gu W; Zhang S
    Front Pharmacol; 2021; 12():719415. PubMed ID: 34721018
    [No Abstract]   [Full Text] [Related]  

  • 20. China's new drug R&D is steadily advancing.
    Xu WF
    Drug Discov Ther; 2007 Aug; 1(1):3. PubMed ID: 22504356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.